Overslaan en naar de inhoud gaan

Hoe kunnen we u helpen?

Deze pagina is niet beschikbaar in deze taal. Deze pagina is beschikbaar in de volgende talen:

  • Engels
  • 26-07-2018

Today, the Court of Justice of the European Union ("CJEU") has rendered a long awaited decision in a dispute revolving around the supplementary protection certificate ("SPC") protecting the hiv inhibitor Truvada. With its judgment rendered (to be found here), the CJEU has now provided much needed clarification on the question of whether "the product is protected by a basic patent in force" within the meaning of Regulation (EC) No 469/2009 concerning the supplementary protection certificate for medicinal products (the "SPC Regulation"), which affords drugs an additional term of protection on top of the standard twenty years provided by the European Patent Convention ("EPC").

Summarised, a combination product is eligible for an SPC, if the claims in the underlying patent relate necessarily and specifically to that combination of active ingredients (even if the combination of activeingredients of which that product is composed is not expressly mentioned in the claims of the basic patent). Read more.

Cookie melding

We care about your privacy. We only use cookies strictly necessary to ensure the proper functioning of our website. You can find more information on cookies and on how we handle your personal data in our Privacy and Cookie Policy.